NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
Ironwood Pharmaceuticals, Inc. IRWD
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$296.2M
▼ 15.7% vs FY2024
EPS · FY25
$0.15
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
8.1%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 296.2M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
8 cents of every revenue dollar became profit this year.
Per share
USD 0.15
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin33.3%
Net margin8.1%
Return on assets6.4%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−5.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−10.3%
−5.3%
+7.1%
+13.6%
Net income
−48.4%
−25.7%
EPS, diluted
−46.1%
−25.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.16B
Shares outstanding, FY2025
Change, 5 years+1.5%
Change, 10 years—
The share count grew 2% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 396.9M
total assets, end of FY2025
Total assetsUSD 396.9M
EquityUSD -261.8M
CashUSD 215.5M
Current ratio1.13×
Equity funds -66% of total assets.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.3
0.4
0.4
0.4
0.4
0.4
0.4
0.3
0.3
0.3
0.1
0.1
0.0
0.2
0.1
0.0
0.0
Operating income $B
0.1
0.1
−0.9
0.3
0.2
0.1
0.1
−0.2
−0.0
−0.1
−0.1
−0.2
−0.3
−0.1
−0.1
−0.1
−0.1
EBITDA $B
0.1
0.1
−0.9
0.3
0.2
0.1
0.1
−0.1
−0.0
−0.0
−0.1
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
Income tax $B
0.0
0.1
0.1
0.1
−0.3
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
0.0
−0.0
−0.0
Net income $B
0.0
0.0
−1.0
0.2
0.5
0.1
0.0
−0.3
−0.1
−0.1
−0.1
−0.2
−0.3
−0.1
−0.1
−0.1
−0.1
EPS, diluted $
0.15
0.01
−6.45
0.96
3.21
0.66
0.14
−1.85
−0.78
−0.56
−1.00
−1.39
−2.35
−0.68
−0.65
−0.59
−10.00
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
−654.9
27.8
158.1
·
·
·
−305.5
−101.0
−155.3
−299.1
−299.3
−57.2
−48.1
−32.5
·
Shares out B
0.16
0.16
0.16
0.15
0.16
0.16
0.00
0.15
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
49 of 49
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed